Millions of older Americans will soon have Medicare access to GLP-1s for weight loss. Here’s what they need to know.
1 min read
The story
Starting July 1, Medicare Part D will begin covering GLP-1 drugs prescribed for obesity — a historic policy reversal that had previously excluded weight-loss medications from Medicare coverage. Millions of eligible Americans aged 65+ now stand to gain access to drugs like semaglutide (Wegovy) and tirzepatide (Zepbound), which have already transformed the commercial market for obesity treatment.
The two dominant names are Novo Nordisk (NVO) and Eli Lilly (LLY), the makers of Wegovy and Zepbound respectively. Both have been in a fierce race to scale manufacturing, lock in formulary placement, and defend pricing — all of which will now face a new test in the price-sensitive Medicare channel, where rebate negotiations tend to compress net realized prices significantly.
The bull case is straightforward: this dramatically expands the total addressable market overnight. Medicare enrollment is large and the obesity prevalence among older adults is high. Any meaningful uptake translates into incremental script volume for LLY and NVO at a time when both companies are still ramping capacity.
The bear case, however, is real. Medicare's negotiating leverage — especially under the Inflation Reduction Act framework — could drive net prices materially lower than the commercial list price. Formulary restrictions and prior authorization hurdles may also throttle actual utilization well below the theoretical ceiling.
The key near-term watch items are formulary inclusion decisions by major Part D plans ahead of July 1, any CMS guidance on coverage criteria and prior auth requirements, and quarterly earnings commentary from LLY and NVO on Medicare channel pricing and volume expectations.
The case — both sides
Medicare's ~65M eligible beneficiaries have disproportionately high obesity rates, and formulary inclusion by major Part D plans would unlock a structural step-change in script volume for both LLY and NVO at a moment when manufacturing capacity is finally scaling to meet demand.
Government payer channels historically negotiate rebates that push net realized prices 50–70% below list, and the Inflation Reduction Act's drug pricing provisions give CMS additional leverage that could make Medicare GLP-1 volume accretive to scripts but dilutive to per-unit economics.
The house read
Two-sidedLLY and NVO face a two-sided test on whether Medicare GLP-1 access expands volume enough to offset the pricing compression that typically comes with the government payer channel.
Wrong ifMedicare net pricing under IRA negotiation frameworks could compress GLP-1 realized revenue per script well below commercial levels, making the volume expansion a margin-dilutive rather than accretive event; additionally, prior authorization and formulary restrictions may severely limit actual uptake in the near term.
Published read · research, not advice